XK 469: Clinical Trials

3 trials of XK 469, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3

Follow XK 469: new trials by email Literature Review of XK 469 trials Research Report on XK 469

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
XK469R in Treating Patients With Refractory Hematologic Cancer
R(+)XK469, pharmacological study, laboratory biomarker analysis - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)602004-10-012013-02-08
XK469 in Treating Patients With Advanced Solid Tumors
R(+)XK469 - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedBarbara Ann Karmanos Cancer Institute222002-01-012014-04-25
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
R(+)XK469 - Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma
Phase 1CompletedNational Cancer Institute (NCI)852001-12-012013-12-16

Conditions studied

Anemia, Refractory, with Excess of Blasts (1)  ·  Blast Crisis (1)  ·  Congenital Abnormalities (1)  ·  Leukemia, Basophilic, Acute (1)  ·  Leukemia, Eosinophilic, Acute (1)  ·  Leukemia, Erythroblastic, Acute (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Megakaryoblastic, Acute (1)  ·  Leukemia, Monocytic, Acute (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myelomonocytic, Acute (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Neuroblastoma (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Barbara Ann Karmanos Cancer Institute (1)

Countries

United States (3)

Top investigators

Francis Giles (1)  ·  Patricia M. LoRusso, DO (1)  ·  Susan Cohn (1)

NIH funding

P30CA022453 (1), U01CA062487 (1), U01CA069852 (1)